USRM Responds to Lawsuit Filed for Discontinued Eye Treatments
20 Dec, 2017, 06:00 ET
MIAMI, Dec. 20, 2017 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today responded to a lawsuit filed last week in Broward County by a plaintiff claiming she had an adverse event for a voluntary stem cell procedure at a doctor's office utilizing autologous (the patient's own) stem cells to attempt to reverse the effects of macular degeneration— a disease that currently has no cure.
The adverse event the plaintiff claims she experienced as a result of the treatment, which was administered by a doctor in February of 2015, is a detached retina in one eye, which the patient alleges has led to loss of sight in that eye. Counsel for the patient also claims that his client's vision has worsened in the other eye. As the lawsuit was just filed, these allegations have not been corroborated. USRM's AdipoCell™ kit was used to harvest autologous cells from the patient's fat tissue.
The use of autologous stem cells for macular degeneration was discontinued by US Stem Cell Clinic, a separate company, as of June of 2015, after adverse events were reported.
"We have addressed any concerns about using AdipoCell™ for macular degeneration by discontinuing its use since more than two years ago," said Dr. Kristin Comella, USRM's Chief Science Officer. "Because we have seen strong safety profiles using AdipoCell™ to harvest autologous stem cells to treat a wide variety of other conditions — including orthopedic, autoimmune, degenerative and neurological diseases — we are instead focusing our development at this time on these more broad arenas."
"Publicly traded companies are always a target for law suits," said Mike Tomas, President & CEO of U.S. Stem Cell, Inc. "Every lawsuit is different, we are confident that our attorneys — who are very familiar with the issues surrounding this case — will investigate and defend this claim so that this case is resolved as soon as legally practical."
U.S. Stem Cell and its affiliated entities did not administer the treatment to the patient. The procedure was performed by an outside practitioner, who is among the hundreds of trained doctors worldwide who utilize U.S. Stem Cell, Inc. technology. U.S. Stem Cell does not currently treat eye patients, and for nearly 20 years, clinics have safely conducted thousands of stem cell procedures utilizing our protocol. We remain committed to the development of effective cell technologies to treat patients with a variety of diseases and injuries.
U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product Adipocell™, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics. To management's knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years, and has certified more than 700 physicians and veterinarians in autologous stem cell therapy worldwide.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue", or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company's business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.
Media Contact: U.S. Stem Cell, Inc.
13794 NW 4th Street, Suite 212
Sunrise, Fl 33325
Email: [email protected]
SOURCE U.S. Stem Cell, Inc.
Share this article